OECD. Fiscal sustainability of health systems: bridging health and finance perspectives. Paris: OECD Publishing; 2015.
Book
Google Scholar
Baumol WJ. Macroeconomics of unbalanced growth: the anatomy of urban crisis. Am Econ Rev. 1967;57(3):415–26.
Google Scholar
Batesa L, Santerre R. Does the U.S. health care sector suffer from Baumol’s cost disease? Evidence from the 50 states. J Health Econ. 2013;32(2):386–91.
Article
Google Scholar
Hartwig J. What drives health care expenditure? Baumol’s model of ‘unbalanced growth’ revisited. J Health Econ. 2008;27(3):603–23.
Article
PubMed
Google Scholar
Scannell J, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11:191–200.
Article
CAS
PubMed
Google Scholar
Paul SM, Mytelka DM, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9:203–14.
Article
CAS
PubMed
Google Scholar
Mahlich J, Yurtoglu B. Returns on different types of investment in the global pharmaceutical industry. Manag Decis Econ. 2019;40(1):16–36.
Article
Google Scholar
Solow R. We’d better watch out. In: New York Times Book Review; 1987. p. 36.
Google Scholar
Acemoglu D, Autor D, Dorn D, Hanson G, Price B. Import competition and the great US employment sag of the 2000s. J Labor Econ. 2016;34(S1):141–98.
Article
Google Scholar
Rotman D. The productivity paradox- Why brilliant AI technologies are not leading to widespread growth and prosperity: MIT Technology review; 2018. Available: https://www.technologyreview.com/2018/06/18/104277/the-productivity-paradox/
Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov. 2011;10:428–38.
Article
CAS
PubMed
Google Scholar
Hay M, Thomas D, Craighead J, Economides C, Rosenthal J. Clinical development success rates for investigational new drugs. Nat Biotechnol. 2014;32(1):40–51.
Article
CAS
PubMed
Google Scholar
FDA. Adaptive designs for clinical trials of drugs and biologics: guidance for industry. Washington; 2019. available: https://www.fda.gov/media/78495/download
EMA. Guidance for companies considering the adaptive pathways approach. 2016; EMA/527726/2016. Available: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-companies-considering-adaptive-pathways-approach_en.pdf. Accessed 1 Aug 2020.
FDA. FDA modernizes clinical trial designs and approaches for drug development, proposing new guidance on the use of adaptive designs and master protocols. 2019, Available: https://www.fda.gov/news-events/fda-brief/fda-brief-fda-modernizes-clinical-trial-designs-and-approaches-drug-development-proposing-new#:~:text=Using%20more%20modern%20approaches%20to,This%20can%20improve%20patient%20access.
Google Scholar
Sydes M, Parmar M, Mason M, Clarke N, Amos C, Anderson J, de Bono J, Dearnaley D, Dwyer J, Green C, Jovic G, Ritchie A, Russell J, Sanders K, Thalmann G, James N. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2013;13:168.
Article
Google Scholar
Chevret S. Bayesian adaptive clinical trials: a dream for statisticians only? Stat Med. 2012;31:1002–13.
Article
PubMed
Google Scholar
Fogel D. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156–64.
Article
PubMed
PubMed Central
Google Scholar
Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med. 2016;176(12):1826–33.
Article
PubMed
Google Scholar
Thorlund K, Haggstrom J, Park J, Mills E. Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ. 2018;360:k698.
Article
PubMed
PubMed Central
Google Scholar
Cerqueira FP, Jesus AMC, Cotrim MD. Adaptive design: a review of the technical, statistical, and regulatory aspects of implementation in a clinical trial. Ther Innov Regul Sci. 2020;54:246–58.
Article
PubMed
Google Scholar
DiMasi J, Grabowski H, Hansen R. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
Article
PubMed
Google Scholar
Hartford A, Thomann M, Chen X, Miller E, Bedding A, Jorgens S, Liu L, Chen L, Morgan C. Adaptive designs: results of 2016 survey on perception and use. Ther Innov Regul Sci. 2020;54(1):42–54.
Article
PubMed
Google Scholar
Adams C, Brantner V. Estimating the cost of new drug development: is it really $802 million? Health Aff. 2006;25(2):420–8.
Article
Google Scholar
Mestre-Ferrandiz J, Sussex J, Towse A. The R&D Cost of a New Medicine. London: Office of Health Economics; 2012.
Google Scholar
Lakdawalla D. Economics of the pharmaceutical industry. J Econ Lit. 2018;56(2):397–449.
Article
Google Scholar
McCutchen W. Estimating the impact of the R&D tax credit on strategic groups in the pharmaceutical industry. Res Policy. 1993;22(4):337–51.
Article
Google Scholar
OECD. Health at a Glance: Business enterprise expenditure for pharmaceutical R&D (BERD) and government budgets for health-related R&D (GBARD). Paris: OECD publishing; 2017.
Google Scholar
Lichtenberg F. Sources of U.S. longevity increase, 1960–2001. Quart Rev Econ Finance. 2004;44(3):369–89.
Article
Google Scholar
US Bureau of Labor Statistics. Historical Consumer Price Index for all Urban Consumers (CPI-U), available at:https://www.bls.gov/cpi/tables/supplemental-files/historical-cpi-u-202001.pdf, Accessed 15 June 2020.
Kairalla JA, Coffey CS, Thomann MA, et al. Adaptive trial designs: a review of barriers and opportunities. Trials. 2012;13:145.
Article
PubMed
PubMed Central
Google Scholar
Kanavos P, Tzouma V, Flannelly C. The impact of regulatory accelerated approval schemes and Htas on access to new oncology medicines: evidence from 11 countries. Value Health. 2018;21(11):S43.
Article
Google Scholar
Eger S, Mahlich J. Pharmaceutical regulation in Europe and its impact on corporate R&D. Heal Econ Rev. 2014;4:23.
Article
Google Scholar
Vernon JA. The relationship between price regulation and pharmaceutical profit margins. Appl Econ Lett. 2003;10:467–70.
Article
Google Scholar
Budish E, Roin B, Williams H. Do firms underinvest in long-term research? Evidence from Cancer clinical trials. Am Econ Rev. 2015;105(7):2044–85.
Article
PubMed
PubMed Central
Google Scholar
Narayan V, Mohwinckel M, Pisano G, et al. Beyond magic bullets: true innovation in health care. Nat Rev Drug Discov. 2013;12:85–6.
Article
CAS
PubMed
Google Scholar
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.
Article
PubMed
PubMed Central
Google Scholar
Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin Investig Drugs. 2017;26(6):735–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Manski C. Adaptive Partial Drug Approval. A Health Policy Proposal. Econ Voice. 2009;6(4):1-5.
Eichler H-G, Oye K, Baird L, Abadie E, Brown J, Drum C, Ferguson J, Garner S, Honig P, Hukkelhoven M, Lim J, Lim R, Lumpkin M, Neil G, O’Rourke B, Pezalla E, Shoda D, Seyfert-Margolis V, Sigal E, Sobotka J, Tan D, Unger T, Hirsch G. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther. 2012;91:426–37.
Article
PubMed
Google Scholar
Schuster B, Brhlikova P, Heath J, McGettigan P. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018. PLoS Med. 2019;16(9):e1002873 Published 2019 Sep 10.
Article
Google Scholar
Garattini S, Gøtzsche P, Jefferson T, et al. Scientists voice concerns about adaptive pathways, 2016. Available: https://epha.org/wp-content/uploads/2016/05/Letter-to-Drs-Rasi-and-Eichler_-13-May-2016.pdf
Google Scholar
EMA. Adaptive pathways reply to Garattini S, Gøtzsche P, Jefferson T et al. 2016. Available: https://www.ema.europa.eu/en/documents/other/ema-response-letter-group-scientists-clarifying-concept-adaptive-pathways_en.pdf. Accessed 1 Aug 2020.
ECPC Rafal Swierzewski, adaptive pathways workshop, 2016. Available: https://www.ema.europa.eu/en/documents/presentation/presentation-patients-views-products-selected-adaptive-pathways-pilot-rafal-swierzewski_en.pdf
Google Scholar
Ermisch M, Bucsics A, Vella Bonanno P, et al. Payers’ views of the changes arising through the possible adoption of adaptive pathways. Front Pharmacol. 2016;7:305.
Article
PubMed
PubMed Central
Google Scholar
IQWiG. 2016. Adaptive pathways: EMA still leaves open questions unanswered. Available: https://www.iqwig.de/en/press/press-releases/adaptive-pathways-ema-still-leaves-open-questions-unanswered.7492.html
Google Scholar
Cummings J, Feldman HH, Scheltens P. The “rights” of precision drug development for Alzheimer’s disease. Alzheimers Res Ther. 2019;11(1):76.
Article
PubMed
PubMed Central
Google Scholar
Lexchin J. Post-market safety warnings for drugs approved in Canada under the notice of compliance with conditions policy. Br J Clin Pharmacol. 2015;79(5):847–59.
Article
PubMed
PubMed Central
Google Scholar
Frank C, Himmelstein DU, Woolhandler S, et al. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals. Health Aff. 2014;33(8):1453–9.
Article
Google Scholar
Olson M. Are novel drugs more risky for patients than less novel drugs? J Health Econ. 2004;23(6):1135–58.
Article
PubMed
Google Scholar
Arnardottir AH, Haaijer-Ruskamp FM, Straus SM, Eichler HG, de Graeff PA, Mol PG. Additional safety risk to exceptionally approved drugs in Europe? Br J Clin Pharmacol. 2011;72(3):490–9.
Article
PubMed
PubMed Central
Google Scholar
Grabowski H, Vernon J, Thomas L. Estimating the effects of regulation on innovation: an international comparative analysis of the pharmaceutical industry. J Law Econ. 1978;24:133–63.
Article
Google Scholar
Peltzman S. An evaluation of consumer protection: the 1962 drug amendments. J Polit Econ. 1973;81:1049–86.
Article
Google Scholar
Wiggins S. Product quality regulation and new drug introductions: some new evidence from the 1970s. Rev Econ Stat. 1981;63:615–9.
Article
Google Scholar
Grabowski H, Vernon J. The Regulation of Pharmaceuticals: Balancing the Benefits and Risks. Washington DC: American Enterprise Institute for Public Policy Research; 1983.
Google Scholar
Blanchard P, Huiban J-P, Musolesi A, Sevestre P. Where there is a will, there is a way? Assessing the impact of obstacles to innovation. Ind Corp Chang. 2013;22(3):679–710.
Article
Google Scholar
Blind K, Petersen S, Riillo C. The impact of standards and regulation on innovation in uncertain markets. Res Policy. 2017;46(1):249–64.
Article
Google Scholar
European Commission, 2016. Better regulations for innovation-driven investment at EU level: commission staff working document. Available at https://ec.europa.eu/research/innovation-union/pdf/innovrefitstaff working document.
Google Scholar
European Commission. The innovation principle. Brussels; 2019. Available: https://ec.europa.eu/info/sites/info/files/research_and_innovation/knowledge_publications_tools_and_data/documents/ec_rtd_factsheet-innovation-principle_2019.pdf
European Commission, 2020. Pharmaceutical Strategy - Timely patient access. Available: https://ec.europa.eu/health/human-use/strategy_en
Google Scholar
Light DW, Lexchin JR. Research and development: what do we get for all that money? BMJ. 2012;345:e4348.
Article
PubMed
Google Scholar
Batta A, Kalra BS, Khirasaria R. Trends in FDA drug approvals over last 2 decades: an observational study. J Fam Med Prim Care. 2020;9(1):105–14.
Article
Google Scholar
Kashoki M, Hanaizi Z, Yordanova S, Veselý R, Bouygues C, Llinares J, Kweder SL. A comparison of EMA and FDA decisions for new drug marketing applications 2014-2016: concordance, discordance, and why. Clin Pharmacol Ther. 2020;107(1):195–202.
Article
PubMed
Google Scholar